Navigation Links
HealthSonix Sells Operating Subsidiaries to Innovative Health Sciences

IRVINE, Calif., July 14 /PRNewswire-FirstCall/ -- HealthSonix, Inc. (Pink Sheets: HSXI)(FWB:H7S) today announced that Innovative Health Sciences, Inc. (Pink Sheets: IHSI) has purchased two wholly owned subsidiaries of HealthSonix, Inc. in exchange for 35,356,000 IHSI common shares.

"Selling the two operating companies to Innovative Health Sciences ( will immediately allow the companies to resume full operations and get back to implementing their business plan," said Dieter Doederlein, Vice President Corporate Development for HealthSonix. "As part of the agreement, Innovative Health Sciences has committed to injecting significant working capital into the operations to expedite the delivery of the Gen II hand held enSonix medical devices and to allow us to expand the distribution of the ZingiberRx Joint and Muscle cream," added Doederlein.

All HealthSonix shareholders of record as of July 14, 2008 will receive IHSI shares on a pro rata basis in exchange for their HSXI shares. The anticipated exchange ratio is .6 IHSI shares for every 1.00 HSXI share. The shares will be distributed to our shareholders in due course.

"Effectively, the current HealthSonix shareholders, as a group, become the majority shareholders in IHSI," said Chris Winter, CEO of Innovative Health Sciences. "Our management and our shareholders are extremely pleased with this acquisition, and we look forward to making our contribution to the immense growth potential and anticipated success of the HealthSonix products."

Following the completion of the transaction, HealthSonix, Inc. will change its name to HSX Holdings, Inc.

HSX Holdings, Inc. (formerly HealthSonix, Inc. - HSXI) is a holding company with ownership interest in Innovative Health Sciences, Inc. [IHSI]. All current HSXI shareholders have indirect ownership in IHSI. For more information, please visit

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

SOURCE HealthSonix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris Sells Quebec City Building for $7.1 million
2. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
3. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
4. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
5. ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates
6. Exelixis Sells 80% Stake in Artemis to Taconic
7. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. IBT Laboratories Names Maureen Loftus President and Chief Operating Officer
10. Studies Show USGI Medicals EndoSurgical Operating System(TM) Enables Incisionless Surgery to Reduce Gastric Pouch and Stoma After Gastric Bypass
11. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
Post Your Comments:
(Date:6/27/2016)...  Alex,s Lemonade Stand Foundation (ALSF), a leading national ... a state-of-the-art bioinformatics lab, using ,big data, to advance ... as Liz Scott , co-executive director of ALSF ... in Washington, D.C. , hosted by ... advocate of pediatric cancer research and awareness. ...
(Date:6/27/2016)...  Global demand for enzymes is forecast to ... $7.2 billion.  This market includes enzymes used in ... production, animal feed, and other markets) and specialty ... and beverages will remain the largest market for ... products containing enzymes in developing regions.  These and ...
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... to enabling healthier lives through the development of innovative ... of the United States denied ... that the claims of Sequenom,s U.S. Patent No. 6,258,540 ... eligibility criteria established by the Supreme Court,s Mayo Collaborative ...
Breaking Biology Technology:
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):